Latest Breaking News On - Klaus sindahl - Page 11 : comparemela.com

Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

/PRNewswire/ Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed.

United kingdomPrnewswire hansa biopharmaHansa biopharmaStephanie kenneyKlaus sindahlProfessor of nephrology at lund universityVp global corporate affairsInternational coordinating investigatorUniversity hospitalEuropean medicinal agencyLund universityHansa biopharma abHealth care amp hospitalsMedical pharmaceuticalsClinical trials amp medical discoveries

Hansa Biopharma AB: Hansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) disease

LUND, Sweden, May 30, 2023 /PRNewswire/ Hansa Biopharma ("Hansa"), a pioneer in enzyme technology for rare immunological conditions, today announced the first patient has been dosed with

United kingdomKlaus sindahlPrnewswire hansa biopharmaHansa biopharmaStephanie kenneyVp global corporate affairsEuropean medicinal agencyInternational coordinating investigatorProfessor of nephrology at lund universityUniversity hospitalLund universityGefallene big techs

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hansa genethonKlaus sindahlHansa biopharmaStephanie bardonStephanie kenneyUnited statesthe companyVp global corporate affairsNasdaq stockholmCorporate affairsMedia relationDuchenne muscular dystrophyLimb girdle muscular dystrophySarepta therapeuticsStatesthe company

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Na

LUND, Sweden and EVRY, France, April 27, 2023 /PRNewswire/ Hansa Biopharma AB, "Hansa", (Nasdaq.

Prnewswire hansa biopharmaStephanie bardonKlaus sindahlStephanie kenneyHansa biopharmaVp global corporate affairsNasdaq stockholmInvestor relationsmCorporate affairsMedia relationDuchenne muscular dystrophyLimb girdle muscular dystrophySarepta therapeutics

Hansa Biopharma interim report January-March 2023

/PRNewswire/ Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and.

United kingdomUnited statesDonato spotaHansa biopharmaMedison pharmaMatthew shaulisStephanie kenneyPrnewswire hansa biopharmaKlaus sindahlImmunology for the international developedVp global corporate affairsChief commercial officerInternational developed marketsNorth america oncologySenior vice presidentHalf year report